S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Meridian Bioscience Stock Forecast, Price & News

+0.48 (+1.58%)
(As of 07/1/2022 08:45 PM ET)
Today's Range
50-Day Range
52-Week Range
414,900 shs
Average Volume
451,661 shs
Market Capitalization
$1.35 billion
P/E Ratio
Dividend Yield
Price Target

Meridian Bioscience MarketRank™ Forecast

Analyst Rating
3.00 Rating Score
2.9% Downside
$30.00 Price Target
Short Interest
6.27% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.03mentions of Meridian Bioscience in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$3.60 M Sold Last Quarter
Proj. Earnings Growth
From $1.44 to $1.18 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.86 out of 5 stars

Medical Sector

667th out of 1,412 stocks

Diagnostic Substances Industry

10th out of 27 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive VIVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Meridian Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Meridian Bioscience logo

About Meridian Bioscience (NASDAQ:VIVO) Stock

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.

VIVO Stock News Headlines

Meridian Bioscience: Correctly Valued
Meridian Bioscience Tops Q2 EPS by 35c
See More Headlines

Industry, Sector and Symbol

Diagnostic substances
Health Care Supplies
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
$71.41 million
Pretax Margin


Sales & Book Value

Annual Sales
$317.90 million
Cash Flow
$2.04 per share
Book Value
$7.57 per share


Free Float
Market Cap
$1.35 billion

Social Links

Meridian Bioscience Frequently Asked Questions

Should I buy or sell Meridian Bioscience stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Meridian Bioscience in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Meridian Bioscience stock.
View analyst ratings for Meridian Bioscience
or view top-rated stocks.

What is Meridian Bioscience's stock price forecast for 2022?

1 brokerages have issued 1 year price objectives for Meridian Bioscience's shares. Their VIVO stock forecasts range from $30.00 to $30.00. On average, they anticipate Meridian Bioscience's stock price to reach $30.00 in the next year. This suggests that the stock has a possible downside of 2.9%.
View analysts' price targets for Meridian Bioscience
or view top-rated stocks among Wall Street analysts.

How has Meridian Bioscience's stock price performed in 2022?

Meridian Bioscience's stock was trading at $20.40 at the beginning of 2022. Since then, VIVO stock has increased by 51.5% and is now trading at $30.90.
View the best growth stocks for 2022 here

When is Meridian Bioscience's next earnings date?

Meridian Bioscience is scheduled to release its next quarterly earnings announcement on Friday, August 5th 2022.
View our earnings forecast for Meridian Bioscience

How were Meridian Bioscience's earnings last quarter?

Meridian Bioscience, Inc. (NASDAQ:VIVO) posted its quarterly earnings results on Friday, May, 6th. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.48 by $0.18. The firm earned $111.23 million during the quarter, compared to the consensus estimate of $99.55 million. Meridian Bioscience had a net margin of 18.34% and a trailing twelve-month return on equity of 18.79%.
View Meridian Bioscience's earnings history

What guidance has Meridian Bioscience issued on next quarter's earnings?

Meridian Bioscience updated its FY 2022 earnings guidance on Monday, June, 6th. The company provided earnings per share guidance of $1.30-$1.40 for the period, compared to the consensus estimate of $1.37. The company issued revenue guidance of $330.00 million-$345.00 million, compared to the consensus revenue estimate of $337.62 million.

Who are Meridian Bioscience's key executives?

Meridian Bioscience's management team includes the following people:
  • Mr. John P. Kenny, Pres, CEO & Director (Age 53, Pay $1.51M)
  • Dr. Lourdes G. Weltzien Ph.D., Exec. VP of Life Science Bus. Unit (Age 57, Pay $665.66k)
  • Mr. Tony Serafini-Lamanna, Exec. VP of Diagnostics (Age 59, Pay $600.53k)
  • Mr. Andrew S. Kitzmiller, Exec. VP & CFO (Age 42)
  • Julie Smith, Sr. VP, Controller & Principal Accounting Officer
  • Mr. Jeff Pinkston, Director of Corp. Fin.
  • Mr. Charles Wood, VP of Corp. Strategy, Bus. Devel. & Investor Relations
  • Ms. Melissa J. McCarey, VP of Global HR
  • Ms. Susan D. Rolih, Consultant (Age 73)
  • Ms. Melissa A. Lueke, Consultant (Age 59)

What is Jack Kenny's approval rating as Meridian Bioscience's CEO?

7 employees have rated Meridian Bioscience CEO Jack Kenny on Glassdoor.com. Jack Kenny has an approval rating of 56% among Meridian Bioscience's employees. This puts Jack Kenny in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Meridian Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Meridian Bioscience investors own include AbbVie (ABBV), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Pfizer (PFE), AT&T (T), Gilead Sciences (GILD), Amgen (AMGN), Alibaba Group (BABA) and Tesla (TSLA).

What is Meridian Bioscience's stock symbol?

Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."

How do I buy shares of Meridian Bioscience?

Shares of VIVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Meridian Bioscience's stock price today?

One share of VIVO stock can currently be purchased for approximately $30.90.

How much money does Meridian Bioscience make?

Meridian Bioscience (NASDAQ:VIVO) has a market capitalization of $1.35 billion and generates $317.90 million in revenue each year. The company earns $71.41 million in net income (profit) each year or $1.409990 on an earnings per share basis.

How many employees does Meridian Bioscience have?

Meridian Bioscience employs 702 workers across the globe.

Does Meridian Bioscience have any subsidiaries?

The following companies are subsidiares of Meridian Bioscience: Exalenz Bioscience.
Read More

When was Meridian Bioscience founded?

Meridian Bioscience was founded in 1977.

How can I contact Meridian Bioscience?

Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The official website for Meridian Bioscience is www.meridianbioscience.com. The company can be reached via phone at (513) 271-3700, via email at mbi@meridianbioscience.com, or via fax at 513-271-3762.

This page (NASDAQ:VIVO) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.